Evoke Pharma, Inc. (EVOK)

Market Cap	7.09M
Revenue (ttm)	2.51M
Net Income (ttm)	-8.22M
Shares Out	3.34M
EPS (ttm)	-2.62
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	29,822
Open	2.27
Previous Close	2.28
Day's Range	2.00 - 2.32
52-Week Range	1.37 - 16.80
Beta	0.40
Analysts	Buy
Price Target	7.14 (+236.79%)
Earnings Date	May 9, 2023

About EVOK

Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray that has completed Phase 3 clinical trials to treat symptoms associated with acute and recurrent diabetic gastroparesis in females. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incor...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Sep 25, 2013
• Employees: 4
• Stock Exchange: NASDAQ
• Ticker Symbol: EVOK

Financial Performance

In 2022, Evoke Pharma's revenue was $2.51 million, an increase of 55.04% compared to the previous year's $1.62 million. Losses were -$8.22 million, -3.68% less than in 2021.

Analyst Forecast

According to 7 analysts, the average rating for EVOK stock is "Buy." The 12-month stock price forecast is $7.14, which is an increase of 236.79% from the latest price.

Price Target

$7.14

(236.79% upside)

Analyst Consensus: Buy